Abstract
For just over a decade, New Zealand has relied on
an independent Crown agency to manage the
public drug benefits scheme. It was established
after a period of industry litigation and unsustainable
budgetary increases. The agency has successfully
contained prices, saving the equivalent
to its originally allocated budget every year,
despite a 50% increase in volumes. It shares
features with similar agencies elsewhere in the
world, particularly in its independence and its
operational methodology. Opposition from the
industry and ambivalence in the medical community
remain matters of concern. The fate of such
agencies is inextricably linked to wider regulatory
and policy settings in the health sector.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献